Search

Reducing bureaucracy in clinical trials: now is the time!

Medical societies and patient advocates across disciplines have joined forces with EHA to call for urgent action to make clinical trials less bureaucratic and more patient-centered, efficient and cheaper.

Read more

Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome

Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome

Limited data are available on major bleeding (MB) occurring during treatment with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) outside clinical…

Read more

Highlights of Past EHA (HOPE) EMEA 2020

Highlights of Past EHA (HOPE) EMEA 2020
October 9-10, 2020
Meeting Chairs:

Prof J Gribben (European Hematology Association)
Prof GH Özsan

In the second weekend of October, EHA and the Turkish Society of Hematology (TSH) kicked-off the very first virtual HOPE meeting.…

Read more

EHA-ISHBT Hematology Tutorial on Hematological Disorders

Dates: February 28-29, 2020
Location: Chandigarh, India
Chairs: N Varma, P Malhotra, J Gribben

Organized by: European Hematology Association (EHA) & Indian Society of Hematology and Blood Transfusion (ISHBT)

EHA will join ISHBT for a fourth time to organize the EHA-ISHBT Hematology Tutorial, this time in Chandigargh,…

Read more

Congress Sponsor Program

Join us at the EHA Annual Congress, where you have the unique opportunity to connect and grow with a community of hematology experts.

Read more

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more